From 2010 to 2016, OVER 50% of people lived five years past their diagnosis compared to roughly
35% of people in 1998. This is due to the approval of new effective treatments.
Clinical trials help bring more multiple myeloma treatments into the marketplace.
ALL treatments in the United States MUST go through clinical trials to be cleared by the FDA. Treatments set in clinical trials can be investigative and may not have been proven to be safe or effective for use.
Unfortunately, people of color have historically been under-represented in the healthcare system. Some people may have hesitations about joining a clinical trial. Furthermore, the options for clinical trials haven’t been offered to all patients equally.
Recently, there’s been a more focused effort to include people of color in clinical trials to
better reflect the diversity of the country.
Of course, enrolling in a clinical trial is a carefully considered decision made by
both you and your doctor.
All trials have their risks and benefits, but contrary to what many believe, there is
absolutely no possibility a patient will receive a placebo (a harmless substance
doesn’t act as medicine) instead of actual treatment in multiple myeloma
Are you aware that African American patients in over a decade of national clinical trials for multiple myeloma had no statistically significant differences in response or survival rates from other patients?
For more information, it’s always best to talk to your doctor.